INHIBITORY EFFECTS OF COMBINED CHEMOTHRAPY WITH FOUR ANTITUMOR AGENTS AGAINST KB CELL IN VITRO

Inhibitory effects on combined chemotherapy with four antitumor agents, Mitomycin C (M), Chromomycin A3 (TM), Cyclophosphamide (E), and Triethylen-thiophosphamide (Tespa), against KB cell in vitro were observed in two experimental series. In the first series; only one of four agents was applied to K...

Full description

Saved in:
Bibliographic Details
Published inJapanese Journal of National Medical Services Vol. 24; no. 4; pp. 281 - 290
Main Authors KATSUTA, Keiichi, HISATSUNE, Kazuo, KAJIYAMA, Minoru, MIYAHARA, Hiroji, ATSUMI, Takeshige, DOJO, Masahiro
Format Journal Article
LanguageJapanese
Published Japanese Society of National Medical Services 20.04.1970
Online AccessGet full text

Cover

Loading…
More Information
Summary:Inhibitory effects on combined chemotherapy with four antitumor agents, Mitomycin C (M), Chromomycin A3 (TM), Cyclophosphamide (E), and Triethylen-thiophosphamide (Tespa), against KB cell in vitro were observed in two experimental series. In the first series; only one of four agents was applied to KB cell for three hours a day, and all four agents were used one by one for four days in this fashion. Concentrations of antitumor agents used were as follows: M 0.04mcg/ml, 0.4mcg/ml; TM 0.01mcg/ml, 0.1mcg/ml; E 2.0mcg/ml, 20mcg/ml; Tespa 0.1mcg/ml, 1.0mcg/mcg/ml. In the second series; four agents were added on KB cell for one hour per one agent in the same day for four days. In these series, comparative studies on number of cells, mitotic rate, and morphologic changes of cells between control KB cell and KB cell treated with antitumor agents were carried out. 1) In the first series, considerable inhibitory effect was observed in the series of high concentration of the agents. Inhibitory effect in the low concentration series was appeared to be between that of the high concentration series and that of the control. 2) The similar inhibitory effect to that obtained in the first series was also observed in the second series in both low and high concentrations of the agents. 3) As for combined therapy with antitumor agents, further studies on more effective combination of the agents, doses, duration of treatment should be carried out.
ISSN:0021-1699
1884-8729
DOI:10.11261/iryo1946.24.281